Image Credit: Canva
Most people are aware of type 1 and type 2 diabetes, but did you know there is a type 3 diabetes as well! It is a more obscure term. Although it is not an accepted medical diagnosis, type 3 diabetes has been discussed in the literature as a possible relationship between insulin resistance in the brain and Alzheimer's disease. This link has been described to help explain how metabolic disorders impact brain health, causing cognitive decline and dementia.
Type 3 diabetes is more of a misnomer because it should not be confused with type 3c diabetes, which relates to pancreatic dysfunction. The term "type 3 diabetes," on the other hand, has been loosely used by some scientists to analogously propose that Alzheimer's disease is strongly implicated with insulin resistance in the brain.
This concept was conceptualized by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University in the year 2008. This hypothesis postulated that Alzheimer's disease may be called type 3 diabetes for it bears many similarities with glucose metabolism disorder type 2 diabetes. Their concept arises from the basic principle that insulin is fundamental to blood sugar regulation, but it is also the case with the brain. When brain cells become insulin-resistant, they lose access to glucose, impairing their function.
Research published in the Journal of Diabetes Science and Technology supports this hypothesis by indicating that insulin resistance can be a significant contributor to the occurrence of dementia, also referred to as Alzheimer's. The symptoms of memory loss and diminished reasoning are associated with impaired glucose metabolism in the body, especially in the cerebral tissue.
Although type 3 diabetes is not a "medical term," its symptoms correlate well with Alzheimer's diseases that are known to reduce the ability to think in an efficient manner and bring down brain health. These signs are:
- Loss of memory, especially short-term.
- Poor judgment and judgment ability
- Failure in recognizing people or places familiar once.
- Failure in the process of reading, writing or processing numbers
- Anxiety, agitation, or mood changes.
- Disorganized thoughts or confusion
- Lack of impulse control
As the disease advances, patients may be afflicted with severe complications including an inability to swallow or control their bodily functions. In the final stages, most patients die from fatal complications such as aspiration pneumonia.
This may not be well understood with regards to type 3 diabetes, or the exact link between insulin resistance and Alzheimer's disease. Some identified contributing factors include the following:
Insulin acts as an important regulatory mechanism of brain functions such as memory and cognition. The reduction in insulin signaling may impair metabolism of brain cells, thus bringing about neurodegeneration.
These diseases show a strong relationship and those individuals diagnosed with type 2 diabetes have double chances of getting Alzheimer's. In the two, the main causes can be chronic inflammation, oxidative stress, and a defect in glucose metabolism.
Insulin resistance associated with obesity, stress, and an unhealthy diet is considered a cause that may increase the chances of Alzheimer's disease.
Researches in Frontiers in Neuroscience and The Lancet Neurology have also highlighted that drugs used for antidiabetic medication may be crucial for the prevention or at least slowing down the course of Alzheimer's.
In 2022, in a study in Pharmaceuticals, researchers studied biomarker uptake in brain regions implicated in the faulty uptake and metabolism of blood sugar in Alzheimer’s patients.
Emerging Therapies
Research into such treatments as intranasal insulin has also been promising. Intranasal delivery of insulin directly to the brain has been reported to enhance glucose uptake by brain cells, improve memory, and boost cognitive performance. While such clinical trials have been shown to be successful, additional research is needed for safety and efficacy.
Medications
For patients being aggressive or agitated, antipsychotic drugs may be prescribed; however, therapies such as cognitive rehabilitation as well as cognitive stimulation therapy serve to preserve memory and executive function.
Lifestyle Interventions
Diet, exercise, and stress management are critical in preventing and managing insulin resistance. A review in the Journal of Alzheimer's Disease also highlighted the benefits of Kirtan Kriya meditation, which can regulate genes involved in insulin and glucose metabolism, improve sleep, and reduce inflammation.
Although type 3 diabetes is not officially recognized, its connection to Alzheimer’s disease underscores the importance of proactive measures for brain health. Some prevention strategies include:
1. Healthy Diet
Consuming a balanced diet rich in antioxidants, whole grains, and healthy fats may support brain health.
2. Regular Exercise
Physical activity improves insulin sensitivity, reduces inflammation, and enhances overall metabolic health.
3. Stress Reduction
Mindfulness practices, including meditation, have been shown to lower stress levels, which can reduce the risk of cognitive decline.
The term type 3 diabetes brings out the complex relationship between metabolic disorders and brain health. Even though it is not a recognized medical condition, the concept emphasizes the crucial role of insulin in brain function and its possible contribution to Alzheimer's disease. Continued research will hopefully provide hope for therapies such as intranasal insulin and lifestyle modifications.
Credit: AI
After surgery, radiotherapy could significantly decrease the chances of an atypical meningioma returning, according to a new international phase 3 trial published in The Lancet.
The findings come from the ROAM/EORTC-1308 trial, the first randomised controlled trial to directly test whether patients with a completely removed atypical meningioma benefit from receiving radiotherapy or whether regular scans and observation are enough.
The results could help settle a treatment question that has remained uncertain for years.
Meningiomas are the most common brain tumours in adults. They develop from the meninges, the protective membranes surrounding the brain, and spinal cord.
An atypical meningioma is classified as a WHO grade 2 tumour. Unlike grade 1 meningiomas, that generally grow slowly, grade 2 tumours are more likely to grow again after surgery.
Even when surgeons manage to remove the entire visible tumour, microscopic tumour cells may remain, sparking a risk of recurrence.
Also read: The Gynecological Cancer Symptoms Women Often Mistake for “Normal” Ageing Like
The ROAM/EORTC-1308 trial enrolled 157 patients whose atypical meningiomas had been completely removed surgically. They were randomly assigned to either:
After a median follow-up of about five years, the difference in recurrence was significant. 14% of patients in the radiotherapy group experienced a recurrence, compared to 30% in the observation group. In other words, the risk of recurrence was reduced by nearly half with postoperative radiotherapy.
Additionally, at five years, about 80% of patients receiving radiotherapy remained free of recurrence, compared to about 64% of those who were monitored without immediate radiotherapy.
Also read: After 70% of His Tongue Was Removed For Cancer, Lawyer Regains Speech & Returns To Court
Until now, doctors have had to weigh two approaches after complete surgical removal of an atypical meningioma.
One option is to give radiotherapy immediately, hoping to destroy microscopic tumour cells that surgery may have missed. The other is to monitor the patient with regular brain scans and use radiotherapy if the tumour returns.
The uncertainty existed as strong randomised evidence showing whether immediate radiotherapy actually reduced recurrence had been lacking. The trial helps cement that evidence.
The researchers say that treatment decisions still need to be made jointly by doctors and patients, taking into account possible side effects and the long-term consequences of radiation treatment. Serious radiation-related complications were uncommon in the trial.
The study also did not establish whether the recurrence benefit extends beyond five years. This means that longer follow-up will be needed to gather more evidence. According to the researchers, the findings are expected to shape national and international treatment guidelines.
The options may extend for patients who have undergone complete removal of a WHO grade 2 atypical meningioma. Rather than contemplating “Should we simply watch and wait?”, they can consider moving to a more evidence-based discussion about whether postoperative radiotherapy should be offered upfront.
Credit: iStock
Heart care has been revolutionized in recent decades. New imaging tools, less invasive procedures, implantable devices and digital instruments are allowing doctors to find problems earlier and with more detail. This means that treatment options tend to be more personalized and recovery time can be shortened.
A big part of this shift comes from new tech in heart testing. Doctors can see how big the heart is, what shape it is and how it moves using cardiac CT, MRI and echo. These tests can give specific information on the functioning of the heart. AI is also being looked at for tasks like reading ECG results, analysing heart scans, and tracking patients over time. The American Heart Association says AI may have uses across heart care. At the same time, many tools still need more proof in real clinical settings before they are widely used.
Also read: Don’t Miss a Beat: Why Every Newborn Deserves a Heart Check
Tech is also changing how some heart issues are handled. In the past, some cases needed full open surgery. Now, for certain patients, doctors may use catheter-based or minimally invasive methods instead. Take TAVR as an example. In that approach, a new aortic valve is placed using a catheter. It is positioned inside the older, damaged valve. For the right group of patients, this can avoid open surgery.
Device design is moving forward too. Newer cardiac devices are adding options for people with rhythm problems and other heart conditions. Leadless pacemakers are one example. These devices are meant to support heart rhythm in an effective way while reducing some drawbacks seen with older device types.
Remote monitoring and wearable tools are growing fast. Some devices can track things like heart rate all day. That can reveal issues that someone might not notice on their own. Still, these tools should sit alongside routine checkups. They should not be used to diagnose yourself.
At the end of the day, the goal is not to swap out a cardiologist for a machine. Tech should help doctors gather clearer data. It can also support more accurate procedures. It may even spot disease earlier than before. What treatment makes sense varies from person to person. Doctors weigh age, past health, how bad the condition is, the test results, and the overall level of risk. As new heart devices keep coming, doctors will need solid proof and good judgment about who should use them. That is how new ideas lead to real gains in heart care.
Credit: iStock
She came to the hospital because of a cough that would not go away. The cough was eventually found to be nothing serious. But her CT scan revealed something unexpected — a 12 mm nodule in the outer part of her right lung.
She had never smoked. She felt completely well.
Yet that tiny shadow raised a big question: was it an old tuberculosis scar, a harmless growth, or an early lung cancer?
A CT scan can show us that a nodule is there. It cannot always tell us what it is.
This is an increasingly familiar situation. As CT scans have become more widely used, particularly after the COVID-19 pandemic, doctors are finding small lung nodules in people being scanned for entirely different reasons. Most turn out to be benign. Some, however, need closer assessment.
India has another challenge. Tuberculosis and its scars are common, and a lung shadow can sometimes be attributed to TB without tissue confirmation. While treating tuberculosis promptly is important, assuming that every suspicious nodule is TB can occasionally delay the diagnosis of something else, including cancer.
The answer, when appropriate, is to obtain a tissue sample.
Traditionally, a small nodule deep in the lung could be difficult to reach. A needle biopsy through the chest can be effective but carries a risk of a collapsed lung. Conventional bronchoscopy is excellent for the larger airways but becomes more challenging as the target gets smaller and farther towards the edge of the lung. Surgery may sometimes be necessary.
Navigation bronchoscopy uses the patient's CT scan to create a three-dimensional map of the airways and guide a thin catheter towards the nodule. Cone Beam CT adds real-time three-dimensional imaging during the procedure, allowing the doctor to check where the instruments are in relation to the lesion before taking the biopsy.
In simple terms, navigation helps us find the way; Cone Beam CT helps us confirm we are there.
The tissue can then be examined immediately where appropriate, helping determine whether the sample is adequate and whether additional material is needed for advanced testing.
Importantly, not every nodule needs a biopsy. Many are best managed through carefully planned follow-up scans. The decision depends on the nodule's size and appearance, previous scans, and the patient's overall risk.
For patients, the message is reassuring: a lung nodule does not mean cancer. But it should not be ignored either.
Keep previous scans. Ask what the likely possibilities are. Understand why your doctor recommends surveillance or biopsy — and make sure the follow-up happens.
Today, advanced bronchoscopy is helping doctors turn a worrying shadow into something much more useful: an answer.
(By Dr Shyam Krishnan, Intervention Pulmonologist, CMRI)
© $2026 Times Horizon Private Limited